ASYMCHEM LAB.(TIAN.)H YC1 (7K90) - Total Liabilities

Latest as of March 2026: €2.74 Billion EUR ≈ $3.21 Billion USD

Based on the latest financial reports, ASYMCHEM LAB.(TIAN.)H YC1 (7K90) has total liabilities worth €2.74 Billion EUR (≈ $3.21 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of ASYMCHEM LAB.(TIAN.)H YC1 to track the company's year-over-year net asset growth rate.

ASYMCHEM LAB.(TIAN.)H YC1 - Total Liabilities Trend (2021–2025)

This chart illustrates how ASYMCHEM LAB.(TIAN.)H YC1's total liabilities have evolved over time, based on quarterly financial data. See ASYMCHEM LAB.(TIAN.)H YC1 (7K90) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

ASYMCHEM LAB.(TIAN.)H YC1 Competitors by Total Liabilities

The table below lists competitors of ASYMCHEM LAB.(TIAN.)H YC1 ranked by their total liabilities.

Company Country Total Liabilities
Beijing Yuanlong Yato Culture Dissemination Co Ltd
SHE:002878
China CN¥839.83 Million
Diageo PLC
LSE:DGE
UK GBX36.14 Billion
Qingdao Vland Biotech Co Ltd
SHG:603739
China CN¥1.14 Billion
Capital A Berhad
KLSE:5099
Malaysia RM6.46 Billion
NAPATECH A/S NAM. DK 025
F:NAT
Germany €67.26 Million
Baotek Industrial Materials Ltd
TWO:5340
Taiwan NT$607.05 Million
King’s Town Construction Co Ltd
TW:2524
Taiwan NT$18.80 Billion
Morguard North American Residential Real Estate Investment Trust
TO:MRG-UN
Canada CA$2.46 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down ASYMCHEM LAB.(TIAN.)H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ASYMCHEM LAB.(TIAN.)H YC1 stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.69 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.15 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.13 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ASYMCHEM LAB.(TIAN.)H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ASYMCHEM LAB.(TIAN.)H YC1 (2021–2025)

The table below shows the annual total liabilities of ASYMCHEM LAB.(TIAN.)H YC1 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €2.63 Billion
≈ $3.08 Billion
+8.46%
2024-12-31 €2.43 Billion
≈ $2.84 Billion
+7.48%
2023-12-31 €2.26 Billion
≈ $2.64 Billion
-11.28%
2022-12-31 €2.54 Billion
≈ $2.97 Billion
-0.08%
2021-12-31 €2.55 Billion
≈ $2.98 Billion
--

About ASYMCHEM LAB.(TIAN.)H YC1

F:7K90 Germany Biotechnology
Market Cap
$426.29 Million
€364.63 Million EUR
Market Cap Rank
#12817 Global
#1371 in Germany
Share Price
€13.10
Change (1 day)
+0.77%
52-Week Range
€7.45 - €14.50
All Time High
€14.50
About

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more